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Aims Extracts from pine tree bark containing a variety of flavonoids have been used in traditional medicine. Pycnogenol is a
proprietary bark extract of the French maritime pine tree (Pinus pinaster ssp. atlantica) that exerts antioxidative, anti-
inflammatory, and anti-platelet effects. However, the effects of Pycnogenol on endothelial dysfunction, a precursor of
atherosclerosis and cardiovascular events, remain still elusive.
Methods
and results
Twenty-three patients with coronary artery disease (CAD) completed this randomized, double-blind, placebo-con-
trolled cross-over study. Patients received Pycnogenol (200 mg/day) for 8 weeks followed by placebo or vice versa
on top of standard cardiovascular therapy. Between the two treatment periods, a 2-week washout period was sched-
uled. At baseline and after each treatment period, endothelial function, non-invasively assessed by flow-mediated dila-
tation (FMD) of the brachial artery using high-resolution ultrasound, biomarkers of oxidative stress and inflammation,
platelet adhesion, and 24 h blood pressure monitoring were evaluated. In CAD patients, Pycnogenol treatment was
associated with an improvement of FMD from 5.3+2.6 to 7.0+ 3.1 (P, 0.0001), while no change was observed
with placebo (5.4+2.4 to 4.7+ 2.0; P ¼ 0.051). This difference between study groups was significant [estimated
treatment effect 2.75; 95% confidence interval (CI): 1.75, 3.75, P, 0.0001]. 15-F2t-Isoprostane, an index of oxidative
stress, significantly decreased from 0.71+ 0.09 to 0.66+0.13 after Pycnogenol treatment, while no change was
observed in the placebo group (mean difference 0.06 pg/mL with an associated 95% CI (0.01, 0.11), P ¼ 0.012]. Inflam-
mation markers, platelet adhesion, and blood pressure did not change after treatment with Pycnogenol or placebo.
Conclusion This study provides the first evidence that the antioxidant Pycnogenol improves endothelial function in patients with
CAD by reducing oxidative stress.
Clinical Trial Registration: ClinicalTrials.gov identifier: NCT00641758
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Introduction
Extracts from pine tree bark have been used in traditional medi-
cine. Pycnogenol is a bark extract of the French maritime pine
tree (Pinus pinaster ssp. atlantica). The extract is prepared using a
standardized procedure that includes an extraction of fresh pine
bark with ethanol and water according to the requirements pub-
lished by the United States Pharmacopoeia (USP).1 The resulting
product is a mixture of flavonoids as monomers, i.e. catechin
and taxifolin, and condensed polymers (85%), as well as dodeoa-
meric flavonols, designated as procyanidins, differing in structure
and chain length. Procyanidins are biopolymers composed of cat-
echin and epicatechin, widely distributed in the plant kingdom.
Many edible fruits contain procyanidins, e.g. apples, berries,
peanuts, and grapes. Additionally, the extract contains phenolic
acids as gallic, caffeic, and ferulic acid as minor constituents. Pycno-
genol also contains glycosylation products, i.e. sugar derivatives of
phenolcarbonic acids and taxifolin.2 These molecules have antioxi-
dant properties and may act as modulators of metabolic enzymes
and other cellular functions.2
In a pharmacokinetic study, healthy volunteers ingested a single
dose of 300 mg and repeated doses of 200 mg Pycnogenol.3 In
blood samples, catechin, taxifolin, ferulic acid, caffeic acid, and
the metabolite 5-(3′,4′-dihydroxyphenyl)-g-valerolactone (M1)
were detected in concentrations up to 100 ng/mL. While the
first four compounds are genuinely present in the maritime pine
bark extract, the metabolite M1 is formed in vivo from catechin
polymers by gut microbiota.4,5 This metabolite had been previously
also found in urine samples after Pycnogenol intake.6 Additionally
to these known constituents and metabolites, 10 yet unknown com-
pounds were detected in human plasma samples.7
The effects of the identified compounds have been investigated
in vitro with the metabolite M1 revealing the highest activity. On a
microgram per millilitre basis, M1 was more potent than the origin-
al maritime pine bark extract in inhibiting the activity of matrix
metalloproteinase (MMP)-1, -2 and -9.3 M1 was also about twice
as potent as hydrocortisone in inhibiting the release of MMP-9
from freshly isolated human monocytes after stimulation with bac-
terial lipopolysaccharide. Thus, it appears very likely that M1 plays a
major role in mediating the biological effects of Pycnogenol.
However, it cannot be excluded that other yet unknown compo-
nents or metabolites of Pycnogenol also contribute to its biological
activity. Plasma samples of volunteers who ingested Pycnogenol-
contained bioactive compounds which in addition to the inhibition
of MMP-9 release statistically significantly inhibited nuclear factor
kappa B (NF-kB) activation8 as well as cyclooxygenase 1 and 2
activity.9
Pycnogenol has been shown to exert anti-inflammatory effects
and to inhibit platelet aggregation, both risk factors for cardiovas-
cular disease.2 In vitro, Pycnogenol prolonged the ascorbate radical
lifetime to the greatest extent by regenerating ascorbic acid.10
Similarly, Pycnogenol inhibits LDL peroxidation, lipid peroxidation
in phospholipid liposomes,2 and lipid peroxidation caused by
t-butylhydroperoxide. Furthermore, Pycnogenol has antioxidant
activity.10 Finally, in isolated blood vessels, Pycnogenol inhibits
vasoconstriction caused by adrenalin via the production of nitric
oxide.11 The present study was designed to evaluate the effect
of Pycnogenol on endothelial function in patients with coronary
artery disease (CAD).
Methods
Study population
Patients with CAD, documented by coronary angiography, nuclear
imaging, or a positive stress test, on stable cardiovascular medication
for at least 1 month and ≥18 years of age, who gave written informed
consent, were recruited at the Clinic of Cardiology, Cardiovascular
Center, University Hospital Zurich, Switzerland.
Exclusion criteria were acute myocardial infarction, unstable angina,
stroke, or coronary intervention/revascularization procedure within
3 months prior to study entry; uncontrolled symptomatic congestive
heart failure (New York Heart Association functional class .II) in
the last 4 weeks prior to study entry; smoking, alcohol, or illicit sub-
stance abuse; uncontrolled blood pressure despite adequate therapy
(≥160/100 mmHg); symptomatic hypotension; ventricular tachyar-
rhythmias; any cardiomyopathy, untreated thyroid dysfunction, or
adrenal insufficiency; renal failure (creatinine clearance using the
MDRD formula12 ,50 mL/min); liver disease; chronic use of long-
acting nitrates; oral or intravenous steroid therapy; insulin-dependent
diabetes mellitus; anaemia (Hb, 10 g/dL); known hypersensitivity to
Pycnogenol; systemic inflammatory diseases (e.g. rheumatoid arthritis,
Crohn’s disease); known human immunodeficiency virus infection or
active virus—hepatitis; pregnancy or breast-feeding, women with child-
bearing potential without adequate contraception; malignancy (unless
healed or in remission .5 years); recipient of any major organ trans-
plant (e.g. lung, liver, heart) or renal replacement therapy and the par-
ticipation in another study within the last month.
Study design and protocol
In this single-centre, prospective, randomized, double-blind, placebo-
controlled study in a cross-over fashion, we analysed the impact of
Pycnogenol on endothelium-dependent and -independent dilatation
in patients with stable CAD receiving optimal standard therapy. Pre-
specified secondary endpoints were change in high-sensitive C-reactive
protein and CD40 Ligand; change in total antioxidative capacity, oxi-
dized LDL (oxLDL), and 8-isoprostanes; change in ambulatory blood
pressure (ABP); and change in shear stress-dependent platelet func-
tion. The protocol was approved by the Institutional Review Board
(Ethics Committee of the Canton Zurich) and the Swiss Agency for
Therapeutic Products (Swissmedic, Bern, Switzerland). The study
was registered at ClinicalTrials.gov (Identifier: NCT00641758).
After screening and recruiting, the patients were randomly assigned
into two groups. For randomization, an unpredictable allocation se-
quence was provided by external institutions (InterCorNet, Zurich,
Switzerland), which were responsible for the blinding and labelling of
the drugs. The study drug and placebo were prepared in identical cap-
sules to ensure uniform appearance of both formulations by the manu-
facturer Horphag Research (UK) Ltd, London, UK. All investigators
including the ultrasonographers were unaware of the allocation pro-
cedure at any time. The patients were randomized to receive either
Pycnogenol 200 mg/day or matching placebo in the first part or vice
versa in the second part with a washout period of 2 weeks in-between.
At each visit (baseline and after 8, 10, and 18 weeks), endothelial
function and ABP were measured, blood samples were drawn, the clin-
ical status was assessed, and adverse events were recorded. At each
visit, a safety analysis was performed including assessment of electro-
lytes, of liver and kidney function, as well as a white and red blood
cell count. Pregnancy testing in women with childbearing potential
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was performed only at the first visit. The patients were advised not to
take their usual drugs in the morning of the examination day (all exam-
inations and measurements were performed in the morning); more-
over, the medical therapy was unchanged throughout the study.
Blood samples and the evaluation of flow-mediated dilatation (FMD)
were performed before the patients took their medications. The
regular medications and the study drug were taken thereafter and
before the 24 h ABP measurement was placed.
Endothelium-dependent and -independent
vasodilatation
Flow-mediated dilatation was performed according to the current
guidelines13,14 and as described previously.15 In brief, a B-mode high-
resolution ultrasound scan of the left brachial artery was obtained
by highly trained and experienced sonographers in a longitudinal
section between 2 and 10 cm above the elbow, using a high-resolution
10 MHz linear array transducer and a high-resolution ultrasound
system Siemens X300 (Siemens Switzerland AG, Zurich, Switzerland).
The analogue video signal was acquired with a video processing system
that computed the artery diameter in real-time (FMD Studio,16 a
system for real-time measurement, Institute of Clinical Physiology,
Pisa, Italy). The high reproducibility of the method has been demon-
strated recently.17,18 The baseline vessel size was considered as the
mean of the measures obtained during the first minute. Flow-mediated
dilatation was calculated as the maximal per cent increase in diameter
above the baseline. Endothelium-independent dilatation was measured
after sublingual glycerol trinitrate (GTN; 0.4 mg, Nitrolingual Spray,
Pohl-Boskamp, Hohenlockstedt, Germany) application by recording
arterial diameter continuously for at least 6 min. The response to
GTN is calculated as the maximum per cent increase in vessel size
above the baseline. The reproducibility of our laboratory was pub-
lished previously.15
Special laboratory analysis
Oxidative stress markers
8-Epi-PGF2alpha (15-F2t-isoprostane) was measured in the plasma with
an 8-Isoprostane Enzyme Immunoassay [8-isoprostane Express EIA Kit,
Cayman Chemicals, Ann Arbor, MI, USA; intra-assay coefficient of vari-
ation (CV) 7.2%, inter-assay CV 15.5%].
High-sensitivity C-reactive protein
A high-sensitive immunoluminometric assay (Imulite 2002, DCP, Los
Angeles, CA, USA) was used to measure high-sensitivity C-reactive
protein levels as described by Wood et al.19
Soluble intercellular adhesion molecule-1, soluble
vascular cell adhesion molecule-1, soluble CD40 Ligand,
and oxidized low-density lipoprotein
EDTA plasma was drawn from each patient and immediately frozen at
2708C. Plasma samples were thawed only once for aliquotation
before they were subjected to analyses. Quantitative detection of
soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular
cell adhesion molecule-1 (sVCAM-1), soluble CD40 Ligand
(sCD40L) (all Bender Med Systems, Vienna, Austria), oxLDL (Immun-
diagnostik, Bernsheim, Germany), and of Lipoprotein-associated
phospholipase A2 (Lp-PLA2) (Uscn Life Sciences Inc., Wuhan, China)
was performed using enzyme-linked immunosorbent assays (ELISA)
according to the manufacturer’s instructions. Briefly, pre-coated
microwell plates absorbed with specific capture antibodies directed
against the respective molecule were washed thoroughly with the
washing buffers provided. Plasma samples were diluted where
indicated and applied in duplicates before a 1–2 h incubation at
room temperature. Detection of the target molecules was performed
using a horseradish peroxidase-conjugated detection antibody specific
for the respective molecule and visualized during a colour-giving reac-
tion using the provided TMB substrate solution. Absorption was mea-
sured at 450 nm and values were normalized to the respective internal
standards supplied by the manufacturer.
Total antioxidant capacity
Total antioxidant capacity of plasma was measured using the total anti-
oxidant capacity kit (Abcam, Cambridge, UK) according to the manu-
facturer’s instructions. Briefly, plasma was allowed to reduce Cu2+ for
1.5 h at room temperature. Reduced Cu+ was chelated with a colori-
metric probe and absorbance was measured at 570 nm. Results were
expressed as trolox equivalent according to a trolox standard curve.
Endothelin-1
The endothelin-1 (ET-1) sandwich ELISA system from Assay Designs
(Ann Arbor, MI, USA) was used according to the manufacturer’s
instructions to measure ET-1 protein concentrations in EDTA
plasma samples. Briefly, 500 mL of each plasma sample was extracted
with 650 mL extraction solvent [acetone:1 N HCl:water (40:1:5)] and
dried under nitrogen streaming. Reconstituted in 120 mL assay
buffer, samples were employed for testing. The sensitivity of the
assay was determined to be 0.41 pg/mL, the intra-assay CVs were
6.7% at 35.9 pg/mL, 8.9% at 2.3 pg/mL, and 8.8% at 1.1 pg/mL; cross-
reactivity with human Big ET-1, ET-2, and ET-3 was low (human Big
ET-1 , 0.1%, ET-2 ¼ 21%, and ET-3 ¼ 3.6%).
Asymmetric dimethylarginine
Asymmetric dimethylarginine (ADMA) concentration was measured
from plasma samples by a competitive ELISA system including an acyl-
ation step as pre-treatment (DLD Diagnostika GmbH, Hamburg,
Germany), with a standard range from 0.1 to 5.0 mmol/L. Twenty
microlitres of each plasma sample were employed for testing. The de-
tection limit of the system was 0.05 mmol/L. As described previously,20
the intra-assay CVs were 5.7% at 0.66 mmol/L and 6.4% at 1.01 mmol/
L; the inter-assay CV ranged from 8.3 to 10.3%. Cross-reactivity with
arginine and other methylarginines was low [arginine ,0.02%;
NG-monomethyl-L-arginine 1.0%; symmetric dimethylarginine (SDMA)
1.2%]. The correlation coefficients with liquid chromatography–mass
spectrometry and gas chromatography–mass spectrometry were
high (0.991; 0.984), with a good linearity between 0.1 and 5.0 mol/L.
Symmetric dimethylarginine
Symmetric dimethylarginine was measured from serum samples by a
competitive ELISA system including an acylation step as pre-treatment
(DLD Diagnostika GmbH) with a standard range from 0.08 to
3.0 mmol/L. Twenty microlitres of each plasma sample were employed
for testing. The detection limit of the system was 0.05 mmol/L. The
intra-assay CVs were 5.7% at 0.52 mmol/L, 6.1% at 0.75 mmol/L, and
4.7% at 1.72 mmol/L; cross-reactivity with arginine and other methylar-
ginines was low (arginine ,0.01%; NG-monomethyl-L-arginine 0.70%;
ADMA 0.44%).
Ambulatory blood pressure measurement
Ambulatory blood pressure measurements were obtained over 24 h
using the ‘Tracker NIBP 2’ (Delmar, Del Mar Reynolds Medical, Hert-
ford, UK) before and after the active treatment phase according to
recent guidelines.21 Patients were asked to keep their arm calm
while the cuff was inflating and to avoid excessive physical exertion
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during monitoring. The monitors were programmed to take readings
every 15 min during daytime and every 30 min during night-time.
Shear stress-dependent platelet function
Shear stress-dependent platelet function was assessed with a cone and
platelet analyzer as described previously.15,22
Statistical analysis
The primary endpoint was the change in FMD after 8 weeks of treat-
ment with Pycnogenol compared with placebo. Based on previous
studies,23 the estimated sample size for this study is 25 (to show a
difference of 1.3% in FMD with a standard deviation of 1.5%, giving
5% two-sided significance level and 85% power when using a
t-test). Analysis was performed using the Wilcoxon and Mann–
Whitney U-tests (to account for possible non-normality of the end-
points), using methods discussed by Senn.24 That is, we considered
two distinct groups of patients: Group 1 who received Pycnogenol
followed by placebo and Group 2 who received placebo followed
by Pycnogenol. Within each group, data are summarized by examin-
ing within patients changes between Periods 1 and 2 (for Group 1,
this is the change from baseline while on placebo minus the
change in baseline while on Pycnogenol; for Group 2, the change
from baseline while on Pycnogenol minus the change in baseline
while on placebo). These unpaired change scores are then analysed
using an unpaired Wilcoxon and the Mann–Whitney U-test, as pro-
posed by Hill and Armitage,25 and later discussed by Senn.24 Statistic-
al tests were preformed two-sided. The effect of Pycnogenol is
estimated as the average of the two group-specific mean change
scores. The period effect is estimated using the difference in the
two group-specific mean change scores (divided by 2). The carry-
over effect was excluded using an unpaired Wilcoxon test of within-
patient change from baseline including only the first period of treat-
ment. A Bonferroni–Holm26 correction was made if necessary. For
the ‘responder analysis’, patients were divided evenly into groups
based on their FMD to Pycnogenol and placebo. Those with better
responses were considered ‘responders’ and the others, ‘non-
responders’. The analyses for C-reactive protein and 15-F2t-
isoprostane were then performed again separately for the two
groups. Results are presented as mean+ SD or SEM as described.
Analysis of the primary endpoint was performed in the R program-
ming language (R Development Core Team, 2009). The statistical
software package SPSS 17 (SPSS Inc., Chicago, IL, USA) was used
to evaluate difference in the clinical characteristics. Statistical signifi-
cance was accepted at P, 0.05.
Results
Study population
A total of 28 patients were enrolled, 5 patients discontinued the
study prematurely, 3 patients withdrew consent and 2 patients
were excluded for adverse events: one patient in the Pycnogenol
group was hospitalized for acute decompensated heart failure;
one patient in the placebo group was excluded after development
of an itching rash. Therefore, 23 patients (19 males and 4 females)
with a mean age of 63.1+ 7.1 years (range: 49–73 years) and a
body mass index of 27.3+3.3 kg/m2 completed the study proto-
col and were included into the analysis. The mean left ventricular
ejection fraction was 62+10%. With the included 23 patients, the
statistical power of 80% is sufficient to detect differences of 1.3% in
FMD between the two treatments. All patients had stable CAD,
11 patients with one-vessel disease, 1 patient with two-vessel
disease, and 11 patients with three-vessel disease.
Effect of Pycnogenol on
endothelium-dependent and
-independent vasodilatation
After 8-week treatment with Pycnogenol, FMD increased from
5.3+2.6 to 7.0+3.1%, while it remained unchanged in the
placebo group (5.4+2.4 to 4.7+2.0%; Table 1 and Figure 1).
The estimated effect of Pycnogenol on FMD was an increase of
2.75 compared with placebo [mean difference 2.75 with an asso-
ciated 95% confidence interval (CI: 1.75, 3.74), P, 0.0001], a
statistically significant treatment effect. The period effect for
this endpoint was estimated to be 20.32 [95% CI (21.31,
0.68), P ¼ 0.51] and, therefore, not statistically significant. The
endothelium-independent dilatation induced by GTN remained
unchanged before and after treatment with Pycnogenol (Table 1).
Effect of Pycnogenol on ambulatory blood
pressure
Systolic and diastolic ABP remained unchanged before and after
treatment with Pycnogenol (Table 2). The estimated effect of Pyc-
nogenol on systolic blood pressure was an increase of 1.17 mmHg
compared with placebo [mean difference 1.17 mmHg with asso-
ciated 95% CI (24.71, 7.04), P ¼ 0.68], a statistically non-
significant treatment effect. The estimated effect of Pycnogenol
on diastolic blood pressure was an increase of 0.06 mmHg com-
pared with placebo [mean difference 0.06 mmHg with associated
95% CI (23.26, 3.37), P ¼ 0.97], a statistically non-significant treat-
ment effect.
Effect of Pycnogenol on oxidative stress
15-F2t-Isoprostane was reduced significantly after 8-week treat-
ment with Pycnogenol compared with baseline and placebo
(Table 2 and Figure 2). The estimated effect of Pycnogenol on
15-F2t-Isoprostane was a decrease of 0.06 pg/mL compared with
placebo [mean difference 0.06 pg/mL with an associated 95% CI
(0.01, 0.11), P ¼ 0.012], a statistically significant treatment effect.
This effect was even more pronounced, when the patients,
‘responders’ and ‘non-responders’, were analysed. The estimated
effect of Pycnogenol on 15-F2t-Isoprostane (responders) was a de-
crease of 0.1 compared with placebo [mean difference 0.1 with
associated 95% CI (0.00, 0.20), P ¼ 0.045], a statistically significant
treatment effect, while no change was observed in the ‘non-
responders’. The estimated effect of Pycnogenol on 15-F2t-
isoprostane (non-responders) was an increase of 0.04 compared
with placebo [mean difference 0.04 with associated 95% CI
(20.02, 0.10), P ¼ 0.15], which was not statistically significant.
Effect of Pycnogenol on markers of
inflammation
The estimated effect of Pycnogenol on C-reactive protein was an
increase of 2.18 mg/L compared with placebo [mean difference
2.18 mg/L with associated 95% CI (23.35, 7.71), P ¼ 0.42], a stat-
istically non-significant treatment effect. Moreover, all of the
F. Enseleit et al.1592
following parameters remained unchanged before and after treat-
ment with Pycnogenol or placebo (Table 2): total antioxidant cap-
acity [mean difference 20.19 mM with associated 95% CI (22.20,
1.83), P ¼ 0.85], sVCAM [mean difference220.44 ng/mL with asso-
ciated 95% CI (2128.88, 88.00), P ¼ 0.7], sICAM [mean difference
267.38 ng/mL with associated 95% CI (2141.83, 7.07), P ¼
0.073], sCD40L [mean difference 0.02 ng/mL with associated 95%
CI (20.21, 0.25), P ¼ 0.85], and oxLDL [mean difference
22.56 ng/mL with associated 95% CI (218.59, 13.47), P ¼ 0.74],
and Lp-PLA2 [mean difference 74.83 ng/mL with associated 95%
CI (246.10, 195.76), P ¼ 0.21].
Effect of Pycnogenol on symmetric
dimethylarginine, asymmetric
dimethylarginine, and endothelin-1
The estimated effect of Pycnogenol on SDMA was a decrease of
0.06 mM compared with placebo [mean difference 20.06 mM
with associated 95% CI (20.16, 0.04), P ¼ 0.23], a statistically non-
significant treatment effect. The estimated effect of Pycnogenol on
ADMA was a decrease of 0.05 mM compared with placebo [mean
difference 20.05 with associated 95% CI (20.12, 0.03), P ¼ 0.19].
Though 57% of the patients receiving Pycnogenol and only 30% of
the patients taking placebo revealed lower ADMA concentrations
after the respective treatment period, the effect was not statistic-
ally significantly different (Table 2).
The mean ET-1 concentrations of the participants were
throughout at the lower limit of the reported physiological range
between 1.10–2.70 ng/L27 and no statistically significant treatment
effect was observed (Table 2).
Effect of Pycnogenol on shear
stress-dependent platelet function
Shear stress-dependent platelet function did not change after
treatment with Pycnogenol (Table 2). The estimated effect of Pyc-
nogenol on area fraction was a decrease of 0.22 compared with
placebo [mean difference 20.22 with associated 95% CI (21.85,
1.42), P ¼ 0.78], a statistically non-significant treatment effect.
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Table 1 Clinical measures before and after 8-week treatment with Pycnogenol or placebo and concomitant medication
Baseline for treatment period Pycnogenol Baseline for control period Placebo
Clinical parameters
FMD (%) 5.3+2.6 7.0+3.1*,# 5.4+2.4 4.7+2.0
GTN (%) 18.4+5.4 19.4+4.8 19.5+5.4 19.7+5.7
24 h SBP (mmHg) 125.8+8.7 125.5+8.1 124.8+9.7 125.7+8.1
24 h DBP (mmHg) 75.0+7.0 74.3+7.3 73.9+7.5 74.4+6.6
Office SBP (mmHg) 129.9+12.5 131.8+14.5 130.1+12.1 129.8+11.7
Office DBP (mmHg) 77.4+6.8 78.9+7.7 78.9+7.5 79.7+8.0
Office HR (b.p.m.) 58.3+8.3 59.4+9.0 60.3+12.3 57.6+9.9
Concomitant medication
Aspirin 23/23 (100%)
Statin 20/23 (87%)
ACE-inhibitor/ARB 18/23 (78%)
b-Blocker 17/23 (74%)
Diuretics 8/23 (35%)
Calcium-antagonist 4/23 (17%)
Clopidogrel 4/23 (17%)
Ezetimibe 4/23 (17%)
Oral anti-diabetics 4/23 (17%)
Marcoumar 1/23 (4%)
a-Antagonist 1/23 (4%)
*P, 0.05 vs. baseline.
#P, 0.05 vs. placebo.
Figure 1 Flow-mediated dilatation (FMD, %) of the brachial
artery in patients receiving Pycnogenol (black bar) or placebo
(white bar). *P, 0.05 vs. baseline and §P, 0.05 vs. placebo.
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Discussion
This study demonstrates an improvement of endothelial function
after 8-week treatment with the flavonoid extract Pycnogenol at
a dose of 200 mg q.d. when compared with placebo in patients
with stable CAD.
The balance between endothelial function and dysfunction plays
an important role in the initiation and progression of atheroscler-
osis and in the transition from a stable to an unstable disease
state.28 As such, the evaluation of endothelial function has
emerged as an important endpoint in cardiovascular research. A
recent meta-analysis suggests that an impairment of brachial
FMD is strongly associated with the occurrence of future cardio-
vascular events.29 Therefore, preservation or recovery of endothe-
lial function is an important therapeutic aim in the prevention of
arteriosclerosis and its clinical complications such as myocardial in-
farction and stroke. The improvement of endothelial function in
our study was associated with a reduction in 8-isoprostanes, a
maker for oxidative stress, but not with components of the
L-arginine metabolism or markers of inflammation, indicating that
antioxidant properties of the compound appear to be involved.
An improvement of endothelial function has been demonstrated
by Nishioka et al.30 in a randomized, double-blind, placebo-
controlled study, including 16 healthy young men who were rando-
mized to receive either Pycnogenol (180 mg/day) or placebo for
2 weeks. The investigators measured forearm blood flow (FBF)
using strain-gauge plethysmography. They found an augmented
FBF response to acetylcholine (ACh) in the Pycnogenol group,
while no augmentation was seen in the placebo group. However,
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Table 2 Laboratory values before and after treatment with Pycnogenol or placebo
Baseline before treatment
period
Pycnogenol Baseline before control
period
Placebo
Hb (g/L) 14.5+1.2 14.5+1.2 14.6+1.2 14.7+1.2
Hk (%) 41.4+3.2 41.3+3.8 41.1+3.4 41.6+3.3
Sodium (mmol/L) 141.1+2.3 141.6+2.2 141.4+2.1 141.9+2.1
Potassium (mmol/L) 3.9+0.3 3.8+0.4 3.9+0.4 3.8+0.4
Creatinine (mmol/L) 91.7+13.9 90.6+25 91.6+16.7 93.4+14.1
Glucose (mmol/L) 5.7+1.4 5.6+1.3 5.7+1.1 5.7+1.3
TC (mmol/L) 4.6+0.6 4.6+0.7 4.7+0.7 4.8+0.8
HDL-C (mmol/L) 1.4+0.4 1.4+0.4 1.4+0.4 1.4+0.4
LDL-C (mmol/L) 2.5+0.5 2.5+0.6 2.6+0.6 2.7+0.7
TG (mmol/L) 1.4+0.7 1.5+0.7 1.5+0.9 1.5+0.9
ALT (U/L) 27.7+4.9 30.0+7.0 29.4+6.3 29.2+5.4
AST (U/L) 29.5+8.2 31.6+9.3 92.6+9.7 32.9+9.9
High-sensitivity C-reactive protein (mg/L) 1.52+1.37 1.52.+1.33 1.63+1.71 1.91+3.4
Lp-PLA2 (ng/mL) 315.89+23.5 321+27.7 279.4+20.4 368.6+24.8
15-F2t-Isoprostane (pg/mL) 0.71+0.09 0.66+0.13*
,# 0.72+0.09 0.75+0.10
ADMA (mM) 0.47+0.11 0.49+0.11 0.45+0.12 0.50+0.12
SDMA (mM) 0.47+0.13 0.47+0.13 0.45+0.12 0.51+0.13
Endothelin-1 (ng/L) 1.20+0.36 1.27+0.30 1.23+0.27 1.21+0.30
Platelet adhesion (%) 3.84+2.0 3.49+1.45 3.2+1.6 3.2+2.0
Total antioxidant capacity (mM) 10.12+1.65 10.1+1.28 9.65+2.72 9.78+2.70
sVCAM (ng/mL) 869+232 791+226 824+265 783+244
sICAM (ng/mL) 284+90 232+77 277+91 274+130
sCD40L (ng/mL) 0.54+1.11 0.50+1.0 0.54+1.10 0.46+1.01
OxLDL (ng/mL) 77.9+119.0 78.9+123.5 85.8+155.4 88.5+154.0
*P, 0.05 vs. baseline.
#P, 0.05 vs. placebo.
Figure 2 15-F2t-Isoprostane before and after Pycnogenol
(black bar) or placebo (white bar); *P, 0.05 vs. baseline and
§P, 0.05 vs. placebo.
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sodium-nitroprusside response was similar in both treatment
groups and the administration of NG-monomethyl-L-arginine, a
known nitric oxide synthase (NOS) inhibitor, abolished the
Pycnogenol-induced augmentation to FBF response to ACh, sug-
gesting an endothelium-dependent vasodilatation by increased
NO production.
Several lines of evidence suggest that oxidative stress may
promote endothelial dysfunction through different mechanisms.31
First, diverse reactive oxygen species (ROS) are produced at
increased levels within the vessel wall and they individually or in
combination interfere with the function of endothelial and vascular
smooth muscle cells.32 The family of ROS includes highly bioactive,
short-living molecules that are derived from a reduction in molecu-
lar oxygen. Multiple enzyme systems use different substrates as
sources of electrons to produce a variety of ROS, the most im-
portant of which are NO, superoxide (O2
2), hydrogen peroxide
(H2O2), and peroxynitrite (ONOO
2). Many enzyme systems, in-
cluding NAD(P)H oxidase, xanthine oxidase, and uncoupled
NOS among others, contribute to production as well as to degrad-
ation of ROS.33 ONOO2 is an important mediator of lipid perox-
idation and protein nitration, including oxidation of LDL, which has
potent proatherogenic effects.32 NO is a crucial mediator of
endothelium-dependent vasodilatation and also plays a role in
platelet aggregation and in maintaining the balance between
smooth muscle cell growth and differentiation.34 NO is rapidly
inactivated by O2
2 to form ONOO2, a known mechanism of endo-
thelial dysfunction.
The short half-life of ROS makes them ideal signalling molecules,
but it also confounds their measurement in complex biological
systems, particularly in humans in vivo.32 On the other hand,
F2-isoprostanes are associated with oxidative stress and are reli-
able markers of in vivo lipid peroxidation.35 Isoprostanes (iPs) are
a family of prostaglandin (PG)-like compounds formed
non-enzymatically through free radical catalysed attack on esteri-
fied arachidonate followed by enzymatic release from cellular or
lipoprotein phospholipids.32 The measurement of F2-isoprostanes
(F2-iPs), containing F-type ring analogous to PGF2a, provides a
reliable tool for identifying populations with enhanced rates of
lipid peroxidation.32 In addition to their potential usefulness as
indexes of oxidative stress in vivo, 8-iso-PGF2a is a vasoconstrictor
and modulates platelet activation in response to other agonists.32
Interestingly, in our study, 8-iso-PGF2a plasma levels decreased sig-
nificantly by 6.43+16.3% after therapy with Pycnogenol (P ¼
0.012) when compared with placebo (increase of 4.54+11.1%).
Moreover, the pronounced improvement of endothelial function
after 8 weeks of treatment with Pycnogenol in the ‘responder’
group was paralleled by a significant decrease in 15-F2t-
isoprostane, while in patients in the ‘non-responder’ group, no sig-
nificant change was detected. These findings are in line with a study
performed by Ryan et al.,36 who examined the effects of Pycno-
genol on different cognitive and biochemical parameters in a
healthy elderly population (60–85 years old). In this double-blind,
placebo-controlled, matched-pair study, 101 participants received
Pycnogenol (150 mg/day) for 3 months. The participants in the
Pycnogenol group showed an improved working memory and
decreased levels of F2-isoprostanes compared with the control
group.
Indeed, Pycnogenol is able to scavenge both hydroxyl radicals
and superoxide anions37 and increase the activity of superoxide
dismutase, glutathione peroxidase, and catalase.38 These in vitro
effects have been confirmed in healthy subjects, treated with Pyc-
nogenol 150 mg q.d.39 In that study oxygen radical absorption cap-
acity increased by 40% during treatment and returned to baseline
after washout. However, there was no significant change in plasma
lipid peroxidation or in LDL-cholesterol oxidation.39 These data
are in line with our study, showing no changes in plasma lipids in-
cluding oxLDL or in total antioxidative capacity.
Endothelial dysfunction has been linked to elevated blood levels
of ADMA, which is an endogenous inhibitor of NO synthesis.40,41
Even small changes of ADMA concentration alter vascular NO
production. Symmetric dimethylarginine correlates with renal func-
tion and indicates an increased cardiovascular risk.42,43 It has been
shown to increase production of ROS and is associated with atrial
fibrillation and endothelial and platelet activation. Although ADMA
plasma levels tended to be lower after Pycnogenol treatment,
neither the effect on ADMA nor SDMA concentrations reached
statistical significance. Although the L-arginine/NO metabolism
was not studied in particular, our finding strongly suggests that
alterations in the L-arginine/NO metabolisms are unlikely involved
in the endothelial protective effects of Pycnogenol.
Endothelin-1 is a potent vasoconstrictor modulating the release
and action of NO in the vessel wall.44 Furthermore, previous
studies suggested45 that Pycnogenol may lower the plasma levels
of the peptide. However, in the current study, no statistically sig-
nificant effect of the flavonoid extract could be observed. This
might be due to the fact that all participants, although CAD
patients, exhibited low ET-1 plasma levels at the lower limit of
the physiological reference range. Thus, it cannot be excluded
that Pycnogenol might affect vascular ET-1 tissue levels.
The anti-inflammatory properties of Pycnogenol have been
demonstrated in a large variety of studies, both in vitro and in
vivo.46 Pycnogenol is able to inhibit tumour necrosis
factor-a-induced NF-kB activation and adhesion molecule expres-
sion in human umbilical vein endothelial cells.47 In two double-
blind, randomized, placebo-controlled trials in patients with
asthma, the investigators found improved asthma symptom
scores as well as improved pulmonary function, which was paral-
leled by a reduction in plasma, as well as in urine leucotriene con-
centrations after Pycnogenol treatment.48,49 While we could
demonstrate a marked improvement in endothelial function in
stable CAD patients treated with Pycnogenol for 8 weeks, which
was paralleled by a decrease in 15-F2t-isoprostane, we could not
demonstrate an improvement in inflammatory parameters (high-
sensitivity C-reactive protein, sVCAM, sICAM, and sCD40L) or
total antioxidative capacity. This lack of effect may be due to the
sample size, which of course was calculated for the primary
endpoint.
The effects of Pycnogenol on platelet function were investigated
by Araghi-Niknam et al.50 in 60 patients with stable CAD, using the
PFA-100 test with adenosine diphosphate- or arachidonic acid-
induced platelet aggregation. After 4 weeks of treatment with
the flavonoid extract at a dose of 450 mg/day, a significant reduc-
tion in platelet aggregation was observed compared with placebo
or baseline values. However, in our study using Pycnogenol
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200 mg q.d., we did not found any difference in shear stress-
dependent platelet function, which suggests that higher dosages
of Pycnogenol are needed to inhibit platelet function.
Recent studies suggested a blood pressure-lowering effect of
Pycnogenol. In a double-blind, placebo-controlled cross-over
study involving 11 patients, supplementation with Pycnogenol
200 mg q.d. significantly reduced systolic blood pressure of
patients with mild-to-moderate hypertension from 139.9+ 3.3
to 132.7+ 4.18 mmHg (P, 0.05) after 8 weeks of therapy,
while diastolic blood pressure remained stable (93.8+ 1.23 vs.
92+1.7 mmHg, P ¼ NS).48 In another double-blind, placebo-
controlled trial randomizing 58 hypertensive subjects, intake of
100 mg/day Pycnogenol allowed to reduce the dosage of the
calcium channel blocker nifedipine required to maintain normal
blood pressure levels.45 However, we did not find any change in
systolic or diastolic blood pressure in our study. This may be
explained, at least in part by the fact, that the blood pressure in
our study was well controlled at study entry.
Conclusion
This study demonstrates for the first time an improvement of
endothelial function after 8-week treatment with Pycnogenol at a
dose of 200 mg q.d. in patients with stable CAD. Pycnogenol sig-
nificantly reduced oxidative stress as assessed by plasma levels of
8-isoprostanes, but left ADMA and SDMA as well as plasma
ET-1 levels unaffected. The clinical implications of these antioxida-
tive properties of the flavonoid extract need to be confirmed in
large-scale clinical outcome trials.
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